|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling显示文摘The stromal compartment of the tumor microenvironment consists of a heterogeneous set of tissue-resident and tumor-infiltrating cells,which are profoundly moulded by cancer cells.An outstanding question is to what extent this heterogeneity is similar between cancers affecting different organs.Here,we profile 233,591 single cells from patients with lung,colorectal,ovary and breast cancer(n=36)and construct a pan-cancer blueprint of stromal cell heterogeneity using different single-cell RNA and protein-based technologies.We identify 68 stromal cell populations,of which 46 are shared between cancer types and 22 are unique.We also characterise each population phenotypically by highlighting its marker genes,transcription factors,metabolic activities and tissue-specific expression differences.Resident cell types are characterised by substantial tissue specificity,while tumor-infiltrating cell types are largely shared across cancer types.Finally,by applying the blueprint to melanoma tumors treated with checkpoint immunotherapy and identifying a naive CD4+T-cell phenotype predictive of response to checkpoint immunotherapy,we illustrate how it can serve as a guide to interpret scRNA-seq data.In conclusion,by providing a comprehensive blueprint through an interactive web server,we generate the first panoramic view on the shared complexity of stromal cells in different cancers. | Junbin Qian Siel Olbrecht Bram Boeckx Hanne Vos Damya Laoui Emre Etlioglu Els Wauters Valentina Pomella Sara Verbandt Pieter Busschaert Ayse Bassez Amelie Franken Marlies Vanden Bempt Jieyi Xiong Birgit Weynand Yannick van Herck Asier Antoranz Francesca Maria Bosisio Bernard Thienpont Giuseppe Floris Ignace Vergote Ann Smeets Sabine Tejpar Diether Lambrechts | 2020 | Cell Research2020，30，9： | 11 |
| 2 | Altretamine (hexamethylmelamine) in the treatment of platinum resistant ovarian cancer:a phase Ⅱ study显示文摘 | Nina Keldsen Hanne Havsteen Ignace Vergote | 2003 | Gynecol Oncol2003，88，： | 1 |
| 3 | Endometrial stromal sarcoma presenting as postpartum haemorrhage: report of a case with a sole t(10;17)(q22;p13) translocation显示文摘 | Karin Leunen Frederic Amant Maria Debiec-Rychter Romaric Croes Anne Hagemeijer Eric F.P.M Schoenmakers Ignace Vergote | 2003 | Gynecologic Oncology2003，，1： | 1 |
| 4 | Endometrial cancer显示文摘 | Frederic Amant Philippe Moerman Patrick Neven Dirk Timmerman Erik Van Limbergen Ignace Vergote | 2005 | The Lancet2005，，9484： | 1 |
| 5 | Clinical Outcome After Radical Excision of Moderate—Severe Endometriosis With or Without Bowel Resection and Reanastomosis: A Prospective Cohort Study显示文摘 | Christel Meuleman Carl Tomassetti Albert Wolthuis Ben Van Cleynenbreugel Annouschka Laenen Freddy Penninckx Ignace Vergote André D?Hoore Thomas D?Hooghe | 2014 | Annals of Surgery2014，，3： | 1 |
| 6 | Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial显示文摘 | Hannah S. van Meurs Parvin Tajik Michel H.P. Hof Ignace Vergote Gemma G. Kenter Ben Willem J. Mol Marrije R. Buist Patrick M. Bossuyt | 2013 | European Journal of Cancer2013，，： | 1 |
| 7 | Ovarian cancer显示文摘 | Nicoletta Colombo Toon Van Gorp Gabriella Parma Frederic Amant Gemma Gatta Cristiana Sessa Ignace Vergote | 2006 | Critical Reviews in Oncology and Hematology2006，，2： | 1 |
| 8 | Endometrial cancer显示文摘 | Frederic Amant Philippe Moerman Patrick Neven Dirk Timmerman Erik Van Limbergen Ignace Vergote | 2005 | The Lancet . 2005 (9484)2005，，： | 1 |
| 9 | Quality of life considerations in gynecologic cancer显示文摘 | RICHARD T PENSON LARI B WENZEL IGNACE VERGOTE | 2006 | International Federation of Gynecology and Obstetrics2006，，： | 1 |
| 10 | Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome显示文摘 | Ioannis Kalogiannidis Sandrijne Lambrechts Frederic Amant Patrick Neven Toon Van Gorp Ignace Vergote | 2007 | American Journal of Obstetrics and Gynecology2007，，3： | 1 |
| 11 | Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With PlatinumSensitive Recurrent Ovarian Cancer:An IntergrouPTrial of the AGO-OVAR,the NCIC CTG,and the EORTC GCG显示文摘 | Jacobus Pfisterer Marie Plante Ignace Vergote | 2006 | J Clin Oncol2006，24，： | 1 |
| 12 | 奥拉帕利维持治疗BRCA 1/2突变铂敏感复发性卵巢癌患者(SOLO2/ENGOT-Ov21):一项双盲随机对照Ⅲ期试验的最终分析显示文摘背景既往发表的SOLO2/ENGOT-Ov21试验的第一部分研究结果表明,作为BRCA1或BRCA2(BRCA1/2)突变铂敏感型的高级别浆液性或子宫内膜样卵巢癌复发患者使用奥拉帕利可延长无进展生存期。因此,本研究的最终分析目的是研究奥拉帕利对这类患者总生存期的影响。方法本研究是一项在16个国家123个医疗中心进行的双盲、随机、安慰剂对照、Ⅲ期临床试验。纳入标准包括:年龄≥18岁;ECOG体能状态评分基线水平为0~1分;组织学检查确诊为复发性、高级别浆液性或高级别子宫内膜样卵巢癌,包括原发性腹膜癌或输卵管癌;以及既往接受过2种或2种以上铂类药物的治疗方案。入选患者按2∶1分配到奥拉帕利组(150 mg片剂,每日2次口服,共300 mg)或安慰剂组;根据既往化疗后是否缓解以及无铂治疗间隔时长进行分层;受试者、治疗提供者和数据分析人员在治疗分配时均设盲。主要终点是既往已报道过的无进展生存期;总生存期作为重要的次要终点之一,在所有随机分配的患者中进行分析;安全性评估在至少接受过1次给药的所有患者中进行。结果2013年9月3日—2014年11月21日,共295例患者参与了试验并被随机分到奥拉帕利组(196例,66%)或安慰剂组(99例,34%)治疗。奥拉帕利组患者中位随访时间为65.7个月(IQR:63.6~69.3),安慰剂组为64.5个月(IQR:63.4~68.7)。奥拉帕利组中位总生存期为51.7个月(95%CI:41.5~59.1),安慰剂组为38.8个月(95%CI:31.4~48.6)(HR=0.74,95%CI:0.54~1.00,P=0.054)。安慰剂组38%接受PARP抑制剂治疗的患者未作调整。治疗引发的最常见的Ⅲ级以上不良事件为贫血,奥拉帕利组发生率为21%(41/195),安慰剂组为2%(2/99)。 | Andrés Poveda Anne Floquet Jonathan A Ledermann Rebecca Asher Richard T Penson Amit M Oza Jacob Korach Tomasz Huzarski Sandro Pignata Michael Friedlander Alessandra Baldoni Tjoung-Won Park-Simon Kenji Tamura Gabe S Sonke Alla Lisyanskaya Jae-Hoon Kim Elias Abdo Filho Tsveta Milenkova Elizabeth S Lowe Phil Rowe Ignace Vergote Eric Pujade-Lauraine the SOLO/ENGOT-Ovinvestigators 王娟(校) 李征(校) | 2021 | 肿瘤药学2021，11，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员